Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa.

Fribley AM, Evenchik B, Zeng Q, Park BK, Guan JY, Zhang H, Hale TJ, Soengas MS, Kaufman RJ, Wang CY.

J Biol Chem. 2006 Oct 20;281(42):31440-7. Epub 2006 Aug 23.

2.
3.

Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.

Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJ, Rizzo P, Miele L, Nickoloff BJ.

Cancer Res. 2005 Jul 15;65(14):6282-93.

4.

Characterization of bortezomib-adapted I-45 mesothelioma cells.

Zhang L, Littlejohn JE, Cui Y, Cao X, Peddaboina C, Smythe WR.

Mol Cancer. 2010 May 18;9:110. doi: 10.1186/1476-4598-9-110.

6.
7.

Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.

Nawrocki ST, Carew JS, Dunner K Jr, Boise LH, Chiao PJ, Huang P, Abbruzzese JL, McConkey DJ.

Cancer Res. 2005 Dec 15;65(24):11510-9.

8.

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.

Hideshima T, Chauhan D, Ishitsuka K, Yasui H, Raje N, Kumar S, Podar K, Mitsiades C, Hideshima H, Bonham L, Munshi NC, Richardson PG, Singer JW, Anderson KC.

Oncogene. 2005 Apr 28;24(19):3121-9.

PMID:
15735676
10.

Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.

Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R, Amiot M.

Cancer Res. 2007 Jun 1;67(11):5418-24.

11.

The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.

Pérez-Galán P, Roué G, Villamor N, Montserrat E, Campo E, Colomer D.

Blood. 2006 Jan 1;107(1):257-64. Epub 2005 Sep 15.

12.

Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin.

Vaziri SA, Hill J, Chikamori K, Grabowski DR, Takigawa N, Chawla-Sarkar M, Rybicki LR, Gudkov AV, Mekhail T, Bukowski RM, Ganapathi MK, Ganapathi R.

Mol Cancer Ther. 2005 Dec;4(12):1880-90.

13.

Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA.

Nawrocki ST, Carew JS, Maclean KH, Courage JF, Huang P, Houghton JA, Cleveland JL, Giles FJ, McConkey DJ.

Blood. 2008 Oct 1;112(7):2917-26. doi: 10.1182/blood-2007-12-130823. Epub 2008 Jul 18.

14.

Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.

Saulle E, Petronelli A, Pasquini L, Petrucci E, Mariani G, Biffoni M, Ferretti G, Scambia G, Benedetti-Panici P, Cognetti F, Humphreys R, Peschle C, Testa U.

Apoptosis. 2007 Apr;12(4):635-55.

PMID:
17252198
15.

Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress.

Fribley A, Wang CY.

Cancer Biol Ther. 2006 Jul;5(7):745-8. Epub 2006 Jul 1.

PMID:
16861900
16.

Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL.

Bauer JA, Trask DK, Kumar B, Los G, Castro J, Lee JS, Chen J, Wang S, Bradford CR, Carey TE.

Mol Cancer Ther. 2005 Jul;4(7):1096-104.

17.

The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.

Pérez-Galán P, Roué G, Villamor N, Campo E, Colomer D.

Blood. 2007 May 15;109(10):4441-9. Epub 2007 Jan 16.

18.

Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis.

Kraus M, Malenke E, Gogel J, Müller H, Rückrich T, Overkleeft H, Ovaa H, Koscielniak E, Hartmann JT, Driessen C.

Mol Cancer Ther. 2008 Jul;7(7):1940-8. doi: 10.1158/1535-7163.MCT-07-2375.

20.

Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.

Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, Jäck HM, Voll RE.

Cancer Res. 2007 Feb 15;67(4):1783-92.

Items per page

Supplemental Content

Write to the Help Desk